Formation of a metabolic intermediate complex of cytochrome P4502B1 by clorgyline.
The monoamine oxidase inhibitor clorgyline was found to inactivate purified reconstituted cytochrome P450 (P450) 2B1 in a time- and concentration-dependent manner (Sharma et al., Drug Metab. Dispos. 24, 669-675, 1996). In an attempt to explain the mechanism of inactivation, the possibility of the formation of a metabolic intermediate (MI) complex during the metabolism of clorgyline by P4502B1 was investigated. Incubation with clorgyline resulted in an absorbance peak with a maximum at 455 nm in the difference spectrum that is characteristic of an MI complex, and the magnitude of absorbance at 455 nm was dependent on both the concentration of clorgyline and NADPH. The MI complex was relatively stable and did not dissociate on standing or on removal of excess inactivator by a series of dilutions followed by microconcentration. When formed using limiting amounts of NADPH, the MI complex could be dissociated by the addition of 50 microM potassium ferricyanide. Clorgyline did not inactivate the 7-ethoxycoumarin O-deethylase activity of liver microsomes from beta-naphthoflavone-treated rats or the hydroxylation of p-nitrophenol by liver microsomes from pyridine-treated rats. However, low levels of MI complex formation were observed with these microsomes. Maximal MI complex formation was observed with liver microsomes from phenobarbital-treated rats. When the MI complex was dissociated by addition of an oxidant such as potassium ferricyanide (50 microM) in the absence of excess NADPH and excess inactivator, there was almost complete recovery of the catalytic activity of the enzyme and spectrally detectable P450. Thus, formation of the MI complex was responsible for the inactivation of P4502B1 and for the loss of spectrally detectable P450 during the incubation of the P450 with clorgyline in the presence of NADPH.
Sharma
U
U
Department of Pharmacology, School of Medicine, Wayne State University, USA.
Roberts
E S
ES
Hollenberg
P F
PF
D000818:Animals; D002248:Carbon Monoxide / Q000378:metabolism; D002384:Catalysis; D003010:Clorgyline / Q000494:pharmacology*; D019362:Cytochrome P-450 CYP2B1 / Q000187:drug effects* / Q000378:metabolism; D007527:Isoenzymes / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D051381:Rats; D011916:Rats, Inbred F344; D013057:Spectrum Analysis
D007527:Isoenzymes; D008996:Monoamine Oxidase Inhibitors; D002248:Carbon Monoxide; D019362:Cytochrome P-450 CYP2B1; D003010:Clorgyline